AIM Vaccine Co., Ltd.
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:57,805.9 tCO2e/year
Scope 1 Emissions:212.30 tCO2e/year
Scope 2 Emissions:57,593.6 tCO2e/year
Total Energy Consumption:70,674,000 kWh/year
Water Consumption:865,000 m3/year
Waste Generated:175,000 tons/year (approx., including hazardous and non-hazardous)
Carbon Intensity:4,868.0 tons of CO2 equivalent/RMB100 million of revenue
ESG Focus Areas
- Product Safety and Quality
- Human Capital Development
- Product Innovation and R&D
- Corporate Governance
- Compliance Operation
- Anti-corruption and Anti-money Laundering
- Intellectual Property Management
- Employee Benefits and Rights
- Responsible Marketing
- Accessibility of Healthcare Service
- Supplier Management
- Information Safety and Privacy Protection
- Energy Management
- Community Investment
- Hazardous Emissions and Wastes Management
- Greenhouse Gas Emissions
- Utilization of Resources
- Water Resource Management
- Public Charity
- Ecological Environment Protection
- Mitigation of Climate Change
Environmental Achievements
- Waste gas discharge density decreased by 9.9% compared to the previous year
- 100% compliance rate for gas emissions, solid waste emissions, and noise emissions
Social Achievements
- Launched online learning platforms (AIM Classroom and AIM Knowledge Base), increasing average training duration per employee by 37.4% in 2023
- Female employee inclusion at 49.8%, with 34.8% female managers
- Supplied 246 million doses of HBV vaccine for the national immunization program
- No corruption or other litigation and cases related to violations of business ethics
Governance Achievements
- Established a corporate governance structure with the Board of Directors, Supervisory Committee, and Shareholders’ General Meeting
- Established the Audit Committee, Remuneration and Appraisal Committee, Compliance and Risk Control Committee, Nomination Committee, and Strategy Committee
- 100% director attendance rate at 11 Board of Directors meetings in 2023
- No information security incidents or breaches in 2023
- No corruption lawsuits filed against the Group and its employees in 2023
Climate Goals & Targets
Short-term Goals:
- AIM Honesty to reduce solid waste and packaging waste by 1% in 2024
Environmental Challenges
- Potential adverse impacts of extreme weather events on operations
- Increased greenhouse gas discharge density by 14.8% compared to 2022
- Increased usage of dry batteries due to cost-saving measures
- Significant increase in paper usage due to increased production and documentation
Mitigation Strategies
- Developed comprehensive emergency plans, including evacuation plans
- Strengthened maintenance and upgrading of operational equipment
- Improved procurement of dry batteries by selecting higher-quality ones
- Promoting electronic document management system to reduce paper dependence
Supply Chain Management
Supplier Audits: 772 suppliers in 2023, with audits conducted regularly
Responsible Procurement
- Supplier Management Regulations
- Material Supplier Evaluation and Approval Procedures
- Quality Risk Management Regulations
- Interim Measures for Bidding and Tendering Management
Climate-Related Risks & Opportunities
Physical Risks
- Extreme weather events (snowstorms, typhoons, rainstorms)
Reporting Standards
Frameworks Used: United Nations 2030 Agenda for Sustainable Development, Environmental, Social and Governance Reporting Guide (Hong Kong Stock Exchange)
UN Sustainable Development Goals
- 3 Good Health and Well-Being
- 4 Quality Education
- 5 Gender Equality
- 8 Decent Work and Economic Growth
- 9 Industry, Innovation and Infrastructure
- 10 Reduced Inequalities
- 12 Responsible Consumption and Production
- 16 Peace, Justice and Strong Institutions
- 17 Partnerships for the Goals
The Group aligns its ESG management strategy with the UN SDGs, integrating them into daily operations and business activities.
Awards & Recognition
- Most Investable Enterprise in China’s Pharmaceutical Industry for 2022
- Excellent Case for High-Quality Development in the Big Health Industry by Xinhua News Agency for 2023
- Star of Outstanding Achievements in Biomedical Enterprises for 2023
- Top 100 Chinese Pharmaceutical Innovative Enterprises List for 2023
- Top 100 Annual Growth Public Companies by Snowball for 2023
- Outstanding Financial Team for 2023
- Best Investor Relations Project Award and Best Digital Investor Relations Award for 2023